Cotargeting VEGF and Neuropilins with Bevacizumab and Secreted Wnt Inhibitors in Prostate Cancer
Annual rept. 1 Sep 2011-31 Aug 2012
CALIFORNIA UNIV IRVINE
Pagination or Media Count:
The objectives of this proposal are to test hypotheses 1 WIF1 IgG fusion protein has an additive or synergistic effect with anti-VEGF therapy to inhibit tumor growth and metastasis and 2 NRP2 is a wnt target gene and predicts prostate cancer progression. WIF1 IgG fusion protein was produced, but the stability of first fusion protein was poor. Experiments for modification of IgG-WIF1 fusion construct for improving the stability of IgG-WIF1 are in progress. Proposed animal experiments are approved by the UCI IACUC and orthotopic prostate cancer models are established. Chromatin immunoprecipitation ChIP, luciferase assay, mRNA expression, and bioinformatics analyses demonstrates that NRP2 is a Wnt target gene. NRP2 antibody was validated using tissue array slides.
- Medicine and Medical Research